Patients aged 6 to 11 years with cystic fibrosis receiving 24-week once-daily vanzacaftor/tezacaftor/deutivacaftor generally ...

Sionna Therapeutics aims to raise $100 million in an IPO for cystic fibrosis drugs, backed by venture capital, targeting a ...

Pulmonary fibrosis in patients with COVID-19 tends to resolve, while idiopathic pulmonary fibrosis always progresses.

Pulmonary fibrosis is a rare, chronic disease that causes scarring in the lungs, making breathing difficult for people who suffer with it.

"Glox to develop precision antibiotics for cystic fibrosis" was originally created and published by Pharmaceutical Technology ...

A novel once-daily drug showed a comparable efficacy and safety profile as the standard-of-care drug in patients with cystic ...

Bryan Freedman, now defending his client against Blake Lively’s accusations over 'It Ends With Us,' claimed Baldoni’s ...

Some people with cystic fibrosis still do not have access to the life-changing modulator therapy drugs, despite wider EMA ...

Mediar Therapeutics is planning to launch a Phase 2 clinical trial in the first half of 2025 to test its IPF therapy MTX-463.

K grant to accelerate development of Glox Therapeutics' novel precision antibiotics targeting AMR lung infections in people ...

Virtual choir program founder Ashley Ballou-Bonnema shares her selfless story on living with and advocating for a life with the chronic disease.